Both Norway and Spain requested the drug which is known as laboratory grade and made for research in animals, confirmed Canada's CTV News.
The ZMab drug is a forerunner to ZMapp, one of the latest Ebola medicines being used to treat victims worldwide.
Canada’s National Microbiological Laboratory in Winnipeg confirmed on Tuesday that they have sent a supply of the experimental medicine to the two European countries.
Canada's Public Health Agency stated: “The experimental medicine was donated in compassion in order to help with the treatment of patients who are infected by Ebola.”
It is not yet known whether the Ebola patient who is currently being treated in Oslo's University Hospital has received or been given the medicine. Spanish health authorities have confirmed they have not yet given the medicine to the Spanish woman who is infected by the same deadly disease.
ZMab is a forerunner of ZMapp, which is the an experimental medicine used during this year's outbreak. Seven persons have received ZMapp, reported VG.
Canadian health authorities have said they will keep the remainder of their ZMab stock for further research to develop the drug so it is fully tested to be used on people. It will then be kept in store should any infected Canadian citizens need the medicine.
The current Ebola outbreak in West Africa is the worst the world has ever seen. The World Health Organization projected the number of cases will hit 9,000 sometime this week.